Which PASI Outcome Is Most Relevant to the Patients in Real-World Care?

In psoriasis treatment, there is a high need to define meaningful endpoints and differences from the patient perspective to analyze patient-relevant differences of frequently used outcome methods for psoriasis under real-world conditions. A sample of 3116 patients from the German Psoriasis-Registry PsoBest was analyzed for clinical as well as patient-reported outcomes (PRO) after 3- and 6-month treatment. The parameters PASI, DLQI, and PBI were intercorrelated and related to two anchoring variables: (1) patient satisfaction with treatment and (2) perceived complete clearance. Baseline data were as follows: PASI 10.5 ± 9.1, DLQI 12.4 ± 3.4, and PBI 2.7 ± 0.3. There was an almost linear relationship between “complete patient satisfaction” and the relative differences in PASI in the range from PASI 25 to PASI 90. However, there was no additional benefit between PASI 90 and PASI 100. The same finding resulted from the anchoring variable “perception of complete healing”. When related to DLQI outcomes, relative PASI changes as well as absolute changes and PASI at 3 and 6 months showed relevant differences between the PASI classes 25 to 90 but not between PASI 90 and PASI 100. Under real-world conditions, changes in PASI and DLQI reflect patient-relevant benefits.

[1]  Muhammad Usman Rathore,et al.  Dermatology Life Quality Index In Patients Of Psoriasis And Its Correlation With Severity Of Disease. , 2020, Journal of Ayub Medical College, Abbottabad : JAMC.

[2]  P. Tounian,et al.  Psoriasis and metabolic and cardiovascular comorbidities in children: A systematic review. , 2019, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[3]  L. Naldi,et al.  Clinical use of dimethyl fumarate in moderate‐to‐severe plaque‐type psoriasis: a European expert consensus , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  E. H. Thompson,et al.  Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials , 2018, The Lancet.

[5]  A. Kimball,et al.  Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials , 2017, The Lancet.

[6]  S. Langan,et al.  Psoriasis and comorbid diseases: Epidemiology. , 2017, Journal of the American Academy of Dermatology.

[7]  A. Finlay,et al.  A systematic review of the use of quality‐of‐life instruments in randomized controlled trials for psoriasis , 2017, The British journal of dermatology.

[8]  A. Egeberg Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. , 2016, The New England journal of medicine.

[9]  M. D'Angelica,et al.  Outcomes of the Memorial Sloan Kettering Cancer Center International General Surgical Oncology Fellowship. , 2016, Journal of the American College of Surgeons.

[10]  J. Ortonne,et al.  Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. , 2015, Journal of the American Academy of Dermatology.

[11]  E. Derviş,et al.  The relationship between quality of life and the severity of psoriasis in Turkey , 2015, European Journal of Dermatology.

[12]  L. Puig,et al.  PASI90 response: the new standard in therapeutic efficacy for psoriasis , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  A. Kimball,et al.  Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[14]  T. Nijsten,et al.  Measurement of health‐related quality of life in dermatological research and practice: outcome of the EADV Taskforce on Quality of Life , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[15]  L. Miot,et al.  Psoriasis: correlation between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment* , 2013, Anais brasileiros de dermatologia.

[16]  A. García‐Díez,et al.  Comparison of Skindex‐29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis , 2012, The British journal of dermatology.

[17]  U. Mrowietz,et al.  Implementing treatment goals for successful long‐term management of psoriasis , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  M. Augustin,et al.  Characterization of Patient-Reported Outcomes in Moderate to Severe Psoriasis , 2011, Dermatology.

[19]  L. McLeod,et al.  Interpreting patient-reported outcome results: US FDA guidance and emerging methods , 2011, Expert review of pharmacoeconomics & outcomes research.

[20]  F. Aubin,et al.  What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[21]  K. Reich,et al.  Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany , 2008, Dermatology.

[22]  T. Nijsten,et al.  Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in psoriasis patients. , 2007, The Journal of investigative dermatology.

[23]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[24]  L. Naldi,et al.  Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversies. , 2010, Clinics in dermatology.

[25]  M. Augustin,et al.  Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. , 2010, European journal of dermatology : EJD.

[26]  G. Jensen,et al.  Assessment and management , 1998 .

[27]  T Fredriksson,et al.  Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.